In 2006, Arai et al. identified TAR DNA-binding protein of 43 kDa (TDP-43) as the major component of the ubiquitin-positive, tau-negative inclusions that define amyotrophic lateral sclerosis (ALS) and a large subset of frontotemporal lobar degeneration (FTLD), and asked whether the accumulation of TDP-43 in different cellular compartments and cell types is a pathogenic driver, a protective sequestration, or a secondary phenomenon — alongside four biochemical questions about the identity of low-molecular-weight TDP-43 species, the phosphorylation events, the specificity of anti-TDP-43 staining of tau-positive structures, and the physiological role of TDP-43. Four of the five issues Arai et al. raised have since been substantially resolved: the low-molecular-weight bands are phosphorylated, largely caspase-cleaved C-terminal fragments; phosphorylation sites and many responsible kinases and phosphatases have been identified; physiological TDP-43 is a central RNA-processing factor; and TDP-43 pathology in tauopathies is real but distinct from tau inclusions. The surviving open core is the original causal question, now sharpened by cryo-electron microscopy structures of patient-brain TDP-43 filaments and by seeded-aggregation models: which TDP-43 species, in which compartments and cell types, are necessary and/or sufficient for neurodegeneration, and how cytoplasmic gain-of-toxic-function and nuclear loss-of-function combine.

Background

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease in which upper and lower motor neurons progressively die, causing paralysis and respiratory failure; frontotemporal lobar degeneration (FTLD) is the second most common presenile dementia, affecting frontal and temporal lobes and overlapping clinically and pathologically with ALS. For years, a shared histopathological signature of both disorders was the presence of ubiquitin-positive, tau-negative inclusions — abnormal intracellular aggregates that stain for ubiquitin (a small protein tag marking substrates for degradation) but not for tau, the protein of Alzheimer-type tangles. In October 2006, two back-to-back studies (Arai et al.; Neumann et al.) identified the missing component: TAR DNA-binding protein of 43 kDa (TDP-43), a ubiquitous nuclear RNA-binding protein with roles in transcriptional regulation and alternative splicing. TDP-43 carries two RNA-recognition motifs (RRMs, conserved RNA-binding modules) and a C-terminal low-complexity, prion-like domain that promotes self-assembly, plus a nuclear localization signal that keeps the healthy protein in the nucleus. In disease, TDP-43 exits the nucleus and accumulates as distinct lesions: neuronal cytoplasmic inclusions (including skein-like and compact or dense-body-like forms), dystrophic neurites, neuronal intranuclear inclusions, and glial cytoplasmic inclusions in oligodendrocytes. Biochemically, the detergent-insoluble fraction from patient brain contains a full-length species shifted from 43 to about 45 kDa (a mobility shift reversed by phosphatase treatment, indicating abnormal phosphorylation) plus lower-molecular-weight bands of roughly 25 and 35 kDa. This work unified ALS and about half of FTLD as a single 'TDP-43 proteinopathy'; TDP-43 pathology is now known to be present in about 97% of ALS cases and, as the separate age-related process called limbic-predominant age-related TDP-43 encephalopathy (LATE), in a large fraction of aged and Alzheimer's disease brains. The Arai et al. 2006 paper closed with five acknowledged open issues: the molecular identity of the low-molecular-weight TDP-43 bands; the mapping of the phosphorylation sites and identification of the responsible kinases and phosphatases; the pathological significance of TDP-43 accumulation in different compartments and cell types — whether the neuronal intranuclear inclusions, compact cytoplasmic/dense-body-like inclusions, and glial cytoplasmic inclusions are pathogenic drivers, protective sequestrations, or secondary phenomena; the reason a polyclonal anti-TDP-43 antibody, unlike a monoclonal, labeled some tau-positive structures in Pick's disease, Alzheimer's disease, and corticobasal degeneration; and the physiological role of TDP-43 in brain cells. Four of these five issues have since been answered. The low-molecular-weight bands are proteolytically truncated, phosphorylated C-terminal fragments (largely caspase-cleavage products; caspases are intracellular proteases that cleave after specific aspartate residues), as shown by biochemical enrichment, expression studies, and mass spectrometry of patient-brain material. The major phosphorylation sites (including Ser409/Ser410) and many responsible enzymes — kinases such as casein kinase 1, tau-tubulin kinase 1 and 2, and CDC7, and phosphatases PP1, PP2A, and PP2B/calcineurin — have been identified, although whether phosphorylation promotes or limits disease remains contested. Physiological TDP-43 is established as a central splicing regulator binding thousands of RNA targets, whose nuclear loss causes inclusion of cryptic exons (aberrant, nonconserved exonic sequences that healthy TDP-43 actively represses), providing the molecular readout for loss-of-function mechanisms. Double-immunofluorescence studies showed that TDP-43 pathology in Alzheimer's disease and tauopathies, while common, is anatomically and structurally distinct from, not superimposed on, tau inclusions, and phospho-specific antibodies superseded the early polyclonal reagents. Cryo-electron microscopy has determined the atomic structures of the amyloid-like TDP-43 filaments actually deposited in patient brains, revealing a filament core spanning residues 282–360 of the low-complexity domain and distinct conformers across the FTLD-TDP subtypes (types A–C, the standard pathological classification of TDP-43-positive FTLD by the laminar distribution and morphology of inclusions in the cerebral cortex). What has not been settled — and is the open problem — is the causal significance of TDP-43 accumulation itself. Two decades of models (transgenic animals; patient-derived iPSC neurons and glia, where iPSC denotes induced pluripotent stem cells, adult cells reprogrammed into stem cells and differentiated into disease-relevant neural cell types; and seeded-aggregation systems, in which preformed TDP-43 aggregates template the misfolding of soluble endogenous TDP-43, analogous to prion propagation) have produced evidence both for cytoplasmic toxic gain-of-function and for nuclear loss-of-function, without a resolution of how these combine, which molecular species is actually toxic, or whether the visible inclusions kill neurons, protect them by sequestering more toxic soluble species, or merely mark an upstream insult.

Problem Statement

Determine whether the accumulation of TDP-43 in the affected nervous system in ALS and FTLD is a pathogenic driver, a protective sequestration, or a secondary phenomenon — the causal question posed in the source (Arai et al. 2006). Concretely, an answer must: (i) identify which TDP-43 species are necessary and/or sufficient for neurodegeneration — nuclear depletion of functional TDP-43, diffuse cytoplasmic mislocalized protein, condensed phase-separated assemblies (liquid-like condensates formed by weak multivalent interactions of low-complexity domains), defined proteolytic C-terminal fragments, or the patient-brain amyloid conformers whose structures are now known; (ii) assign causal significance to each compartment- and cell-type-specific lesion — neuronal intranuclear inclusions, skein-like and compact/dense-body-like cytoplasmic neuronal inclusions, and glial cytoplasmic inclusions — including whether inclusion formation itself mitigates or mediates neuronal and glial death; and (iii) if accumulation is not entirely secondary, establish how cytoplasmic gain-of-toxic-function and nuclear loss-of-function combine within the same disease, with evidence that is causal rather than correlative and that accounts for the cell-type-specific and disease-subtype-specific (FTLD-TDP types A–C) patterns of human pathology. A demonstration that TDP-43 accumulation is entirely secondary to an upstream cause, with TDP-43 aggregation neither necessary nor sufficient for degeneration, would equally answer the question.

References

  1. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications 351(3):602-611, 2006. DOI: 10.1016/j.bbrc.2006.10.093. https://doi.org/10.1016/j.bbrc.2006.10.093
  2. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130-133, 2006. DOI: 10.1126/science.1134108. https://doi.org/10.1126/science.1134108
  3. Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M, McCluskey LF, Trojanowski JQ, Lee VM. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. American Journal of Pathology 173(1):182-194, 2008. DOI: 10.2353/ajpath.2008.080003. https://doi.org/10.2353/ajpath.2008.080003
  4. Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, Lin WL, Tong J, Castanedes-Casey M, Ash P, Gass J, Rangachari V, Buratti E, Baralle F, Golde TE, Dickson DW, Petrucelli L. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proceedings of the National Academy of Sciences USA 106(18):7607-7612, 2009. DOI: 10.1073/pnas.0900688106. https://doi.org/10.1073/pnas.0900688106
  5. Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ, Lee VM. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. Journal of Biological Chemistry 284(13):8516-8524, 2009. DOI: 10.1074/jbc.M809462200. https://doi.org/10.1074/jbc.M809462200
  6. Kametani F, Obi T, Shishido T, Akatsu H, Murayama S, Saito Y, Yoshida M, Hasegawa M. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Scientific Reports 6:23281, 2016. DOI: 10.1038/srep23281. https://doi.org/10.1038/srep23281
  7. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, König J, Hortobágyi T, Nishimura AL, Zupunski V, Patani R, Chandran S, Rot G, Zupan B, Shaw CE, Ule J. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nature Neuroscience 14(4):452-458, 2011. DOI: 10.1038/nn.2778. https://doi.org/10.1038/nn.2778
  8. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW, Cleveland DW. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature Neuroscience 14(4):459-468, 2011. DOI: 10.1038/nn.2779. https://doi.org/10.1038/nn.2779
  9. Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C, Wancewicz E, Kim AS, Watt A, Freier S, Hicks GG, Donohue JP, Shiue L, Bennett CF, Ravits J, Cleveland DW, Yeo GW. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nature Neuroscience 15(11):1488-1497, 2012. DOI: 10.1038/nn.3230. https://doi.org/10.1038/nn.3230
  10. Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349(6248):650-655, 2015. DOI: 10.1126/science.aab0983. https://doi.org/10.1126/science.aab0983
  11. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Kosaka K, Arai H. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Research 1184:284-294, 2007. DOI: 10.1016/j.brainres.2007.09.048. https://doi.org/10.1016/j.brainres.2007.09.048
  12. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, Coyle-Gilchrist ITS, Chui HC, Fardo DW, Flanagan ME, Halliday G, Hokkanen SRK, Hunter S, Jicha GA, Katsumata Y, Kawas CH, Keene CD, Kovacs GG, Kukull WA, Levey AI, Makkinejad N, Montine TJ, Murayama S, Murray ME, Nag S, Rissman RA, Seeley WW, Sperling RA, White CL 3rd, Yu L, Schneider JA. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142(6):1503-1527, 2019. DOI: 10.1093/brain/awz099. https://doi.org/10.1093/brain/awz099
  13. Riku Y, Iwasaki Y, Ishigaki S, Akagi A, Hasegawa M, Nishioka K, Li Y, Riku M, Ikeuchi T, Fujioka Y, Miyahara H, Sone J, Hattori N, Yoshida M, Katsuno M, Sobue G. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain 145(8):2769-2784, 2022. DOI: 10.1093/brain/awac091. https://doi.org/10.1093/brain/awac091
  14. Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, Ryskeldi-Falcon B. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601(7891):139-143, 2022. DOI: 10.1038/s41586-021-04199-3. https://doi.org/10.1038/s41586-021-04199-3
  15. Arseni D, Chen R, Murzin AG, Peak-Chew SY, Garringer HJ, Newell KL, Kametani F, Robinson AC, Vidal R, Ghetti B, Hasegawa M, Ryskeldi-Falcon B. TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP. Nature 620(7975):898-903, 2023. DOI: 10.1038/s41586-023-06405-w. https://doi.org/10.1038/s41586-023-06405-w
  16. Arseni D, Nonaka T, Jacobsen MH, Murzin AG, Cracco L, Peak-Chew SY, Garringer HJ, Kawakami I, Suzuki H, Onaya M, Saito Y, Murayama S, Geula C, Vidal R, Newell KL, Mesulam M, Ghetti B, Hasegawa M, Ryskeldi-Falcon B. Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP type C. Nature 634(8034):662-668, 2024. DOI: 10.1038/s41586-024-08024-5. https://doi.org/10.1038/s41586-024-08024-5
  17. Gruijs da Silva LA, Simonetti F, Hutten S, Riemenschneider H, Sternburg EL, Pietrek LM, Gebel J, Dötsch V, Edbauer D, Hummer G, Stelzl LS, Dormann D. Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation. EMBO Journal 41(8):e108443, 2022. DOI: 10.15252/embj.2021108443. https://doi.org/10.15252/embj.2021108443
  18. Tian Y, Wang Y, Jablonski AM, Hu Y, Sugam JA, Koglin M, Stachel SJ, Zhou H, Uslaner JM, Parmentier-Batteur S. Tau-tubulin kinase 1 phosphorylates TDP-43 at disease-relevant sites and exacerbates TDP-43 pathology. Neurobiology of Disease 161:105548, 2021. DOI: 10.1016/j.nbd.2021.105548. https://doi.org/10.1016/j.nbd.2021.105548
  19. Kellett EA, Bademosi AT, Walker AK. Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration. Molecular Neurodegeneration 20(1):53, 2025. DOI: 10.1186/s13024-025-00839-8. https://doi.org/10.1186/s13024-025-00839-8
  20. Scialò C, Zhong W, Jagannath S, Wilkins O, Caredio D, Hruska-Plochan M, Lurati F, Peter M, De Cecco E, Celauro L, Aguzzi A, Legname G, Fratta P, Polymenidou M. Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures. Neuron 113(10):1614-1628.e11, 2025. DOI: 10.1016/j.neuron.2025.03.008. https://doi.org/10.1016/j.neuron.2025.03.008
  21. Rummens J, Khalil B, Yıldırım G, Silva P, Zorzini V, Peredo N, Wojno M, Ramakers M, Van Den Bosch L, Van Damme P, Davie K, Hendrix J, Rousseau F, Schymkowitz J, Da Cruz S. TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43. Neuron 113(10):1597-1613.e8, 2025. DOI: 10.1016/j.neuron.2025.03.004. https://doi.org/10.1016/j.neuron.2025.03.004
  22. Zhang L, Huang Y, Huang W, Huang Q, Lin Y, Gu J. TDP-43 phosphorylation: Exploring kinases, phosphatases, and therapeutic potential in neurodegeneration. Journal of Alzheimer's Disease 110(4):1533-1546, 2026. DOI: 10.1177/13872877261424284. https://doi.org/10.1177/13872877261424284
  23. Dahlhaus R, Braun RJ. The role of TDP-43 fragments in regular cellular functions and homeostatic failure. Neurobiology of Disease 222:107349, 2026. DOI: 10.1016/j.nbd.2026.107349. https://doi.org/10.1016/j.nbd.2026.107349
  24. Zangrando L, Buratti E, Paron F. TDP-43 aggregation: The healthy-toxic balance of the prion-like domain. Advanced Science 13(40):e76119, 2026. DOI: 10.1002/advs.76119. https://doi.org/10.1002/advs.76119
  25. Christoforidou E, McFagan E, McLaughlin M, Hafezparast M. TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis. Biochemical Society Transactions 54(7):901-913, 2026. DOI: 10.1042/BST20260896. https://doi.org/10.1042/BST20260896